What is Precipio?
Founded in 2011 and headquartered in New Haven, Connecticut, Precipio operates at the intersection of clinical pathology and advanced cancer research. The company distinguishes itself by partnering with premier academic institutions to bridge the gap between complex diagnostic research and practical clinical application. Its core platform is designed to provide physicians with expert-driven diagnostic insights, thereby enhancing the precision of clinical decision-making. By focusing on high-quality pathology services, Precipio addresses a critical market need for accuracy in cancer detection, ultimately aiming to improve patient outcomes through superior diagnostic intelligence.
How much funding has Precipio raised?
Precipio has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Precipio
PPP
Public-Private Partnership
What's next for Precipio?
With this late-stage capital, Precipio is poised to accelerate its market penetration and expand its diagnostic service offerings. The strategic focus will likely center on scaling its collaborative network with academic research centers to integrate cutting-edge diagnostic methodologies into its existing workflow. As the company matures, the emphasis will shift toward optimizing operational efficiency and broadening its reach within the oncology diagnostics market. This financial backing provides the necessary runway to solidify its competitive advantage and establish a more robust footprint in the precision medicine landscape, ensuring that its diagnostic platform remains at the forefront of clinical innovation.
See full Precipio company page
